124 related articles for article (PubMed ID: 36870373)
1. Oxazolinyl derivatives of androst-16-ene as inhibitors of CYP17A1 activity and prostate carcinoma cells proliferation: Effects of substituents in oxazolinyl moiety.
Latysheva AS; Zolottsev VA; Veselovsky AV; Scherbakov KA; Morozevich GE; Zhdanov DD; Novikov RA; Misharin AY
J Steroid Biochem Mol Biol; 2023 Jun; 230():106280. PubMed ID: 36870373
[TBL] [Abstract][Full Text] [Related]
2. Comparison of [17(20)E]-21-Norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth.
Zolottsev VA; Tkachev YV; Latysheva AS; Kostin VA; Novikov RA; Timofeev VP; Morozevich GE; Kuzikov AV; Shumyantseva VV; Misharin AY
Steroids; 2018 Jan; 129():24-34. PubMed ID: 29183745
[TBL] [Abstract][Full Text] [Related]
3. Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17α-hydroxylase/17,20-lyase (CYP17A1) inhibitors.
Kuzikov AV; Dugin NO; Stulov SV; Shcherbinin DS; Zharkova MS; Tkachev YV; Timofeev VP; Veselovsky AV; Shumyantseva VV; Misharin AY
Steroids; 2014 Oct; 88():66-71. PubMed ID: 24971814
[TBL] [Abstract][Full Text] [Related]
4. New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone.
Latysheva AS; Zolottsev VA; Veselovsky AV; Scherbakov KA; Morozevich GE; Pokrovsky VS; Novikov RA; Timofeev VP; Tkachev YV; Misharin AY
Steroids; 2020 Jan; 153():108534. PubMed ID: 31678134
[TBL] [Abstract][Full Text] [Related]
5. Oxazolinyl derivatives of [17(20)E]-21-norpregnene differing in the structure of A and B rings. Facile synthesis and inhibition of CYP17A1 catalytic activity.
Kostin VA; Zolottsev VA; Kuzikov AV; Masamrekh RA; Shumyantseva VV; Veselovsky AV; Stulov SV; Novikov RA; Timofeev VP; Misharin AY
Steroids; 2016 Nov; 115():114-122. PubMed ID: 27505042
[TBL] [Abstract][Full Text] [Related]
6. 17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
Ajduković JJ; Djurendić EA; Petri ET; Klisurić OR; Celić AS; Sakač MN; Jakimov DS; Gaši KM
Bioorg Med Chem; 2013 Dec; 21(23):7257-66. PubMed ID: 24148837
[TBL] [Abstract][Full Text] [Related]
7. N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
Brossard D; Zhang Y; Haider SM; Sgobba M; Khalid M; Legay R; Duterque-Coquillaud M; Galera P; Rault S; Dallemagne P; Moslemi S; El Kihel L
Chem Biol Drug Des; 2013 Nov; 82(5):620-9. PubMed ID: 23906044
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Biological Evaluation of New Isoxazolyl Steroids as Anti-Prostate Cancer Agents.
Rudovich AS; Peřina M; Krech AV; Novozhilova MY; Tumilovich AM; Shkel TV; Grabovec IP; Kvasnica M; Mada L; Zavialova MG; Mekhtiev AR; Jorda R; Zhabinskii VN; Khripach VA
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362320
[TBL] [Abstract][Full Text] [Related]
9. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
10. [Interaction of novel oxazoline derivatives of 17(20)e-pregna-5,17(20)-diene with cytochrome P450 17A1].
Stulov SV; Dugin NO; Zharkova MS; Shcherbinin DS; Kuzikov AV; Shumyantseva VV; Misharin AY; Veselovsky AV
Biomed Khim; 2016; 62(1):38-44. PubMed ID: 26973185
[TBL] [Abstract][Full Text] [Related]
11. New azole derivatives of [17(20)E]-21-norpregnene: Synthesis and inhibition of prostate carcinoma cell growth.
Dalidovich TS; Hurski AL; Morozevich GE; Latysheva AS; Sushko TA; Strushkevich NV; Gilep AA; Misharin AY; Zhabinskii VN; Khripach VA
Steroids; 2019 Jul; 147():10-18. PubMed ID: 30149075
[TBL] [Abstract][Full Text] [Related]
12. Novel Nitrogen Containing Steroid Derivatives for Prostate Cancer Treatment.
Latysheva AS; Zolottsev VA; Pokrovsky VS; Khan II; Misharin AY
Curr Med Chem; 2021; 28(40):8416-8432. PubMed ID: 33557730
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative, proapoptotic, and tumor-suppressing effects of the novel anticancer agent alsevirone in prostate cancer cells and xenografts.
Khan II; Karshieva SS; Sokolova DV; Spirina TS; Zolottsev VA; Latysheva AS; Anisimova NY; Komarova MV; Yakunina MN; Nitetskaya TA; Misharin AY; Pokrovsky VS
Arch Pharm (Weinheim); 2022 Jan; 355(1):e2100316. PubMed ID: 34668210
[TBL] [Abstract][Full Text] [Related]
14. Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
Petrunak EM; Bart AG; Peng HM; Auchus RJ; Scott EE
J Biol Chem; 2023 Mar; 299(3):102999. PubMed ID: 36773804
[TBL] [Abstract][Full Text] [Related]
15. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
16. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents.
Wróbel TM; Rogova O; Andersen KL; Yadav R; Brixius-Anderko S; Scott EE; Olsen L; Jørgensen FS; Björkling F
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32660148
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
[TBL] [Abstract][Full Text] [Related]
19. Steroselective synthesis of some steroidal oxazolines, as novel potential inhibitors of 17alpha-hydroxylase-C17,20-lyase.
Ondré D; Wölfling J; Tóth I; Szécsi M; Julesz J; Schneider G
Steroids; 2009; 74(13-14):1025-32. PubMed ID: 19666042
[TBL] [Abstract][Full Text] [Related]
20. Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
Li A; Yadav R; White JK; Herroon MK; Callahan BP; Podgorski I; Turro C; Scott EE; Kodanko JJ
Chem Commun (Camb); 2017 Mar; 53(26):3673-3676. PubMed ID: 28304025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
